<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="6904818S1525-0016(19)30458-7 doi: 10.1016/j.ymthe.2019.10.004 : Commentary Repurposing an HIV Drug for" exact="Zika" post="Virus Therapy XieXuping1ShiPei-Yongpeshi@utmb.edu1∗[1], ∗Corresponding author: Pei-Yong Shi, Department of"/>
 <result pre="American Society of Gene and Cell Therapy, 2019 Main Text" exact="Zika" post="virus (ZIKV) is a mosquito-borne flavivirus that can cause"/>
 <result pre="a US Food and Drug Administration (FDA)-approved HIV drug, inhibits" exact="ZIKV" post="RNA-dependent RNA polymerase (RdRp), leading to potent anti-ZIKV activity"/>
 <result pre="repurposing clinically approved drugs for possible prevention and treatment of" exact="ZIKV" post="infection and its associated disease. Although emerging infectious diseases"/>
 <result pre="syndrome (SARS), middle east respiratory syndrome (MERS), Ebola, Nipah, chikungunya," exact="West Nile," post="yellow fever, and ZIKV. Given the unpredictable nature of"/>
 <result pre="blocking the viral RdRp (Figure 1). Figure 1 Rilpivirine Inhibits" exact="ZIKV" post="by Blocking Viral RdRp (A) Proposed rilpivirine binding site"/>
 <result pre="by Blocking Viral RdRp (A) Proposed rilpivirine binding site on" exact="ZIKV" post="RdRp. ZIKV NS5 (PDB: 5TMH)15 contains an N-terminal methyltransferase"/>
 <result pre="Viral RdRp (A) Proposed rilpivirine binding site on ZIKV RdRp." exact="ZIKV" post="NS5 (PDB: 5TMH)15 contains an N-terminal methyltransferase domain (blue)"/>
 <result pre="al.2 found that human primary astrocytes are more susceptible to" exact="ZIKV" post="infection than several other human cell types, including fetal"/>
 <result pre="including fetal microglia, fetal neuron, and neural progenitor cells. Using" exact="ZIKV" post="infection of astrocytes as a screening assay, they identified"/>
 <result pre="astrocytes as a screening assay, they identified rilpivirine as a" exact="ZIKV" post="inhibitor from eight FDA-approved HIV nucleoside and non-nucleoside reverse"/>
 <result pre="reverse transcriptase drugs. Rilpivirine is a non-nucleoside inhibitor and suppressed" exact="ZIKV" post="RNA replication by ∼70% at 5 μM concentration. The"/>
 <result pre="The higher susceptibility of astrocytes than other cell types to" exact="ZIKV" post="infection is intriguing because previous studies suggested that ZIKV"/>
 <result pre="to ZIKV infection is intriguing because previous studies suggested that" exact="ZIKV" post="preferentially infected human neural progenitor cells.6, 7, 8 Since"/>
 <result pre="ZIKV preferentially infected human neural progenitor cells.6, 7, 8 Since" exact="ZIKV" post="was proposed as a potential oncolytic virotherapy for glioblastoma,7,"/>
 <result pre="also inhibits closely related flaviviruses, such as dengue, yellow fever," exact="West Nile," post="and Japanese encephalitis viruses. Nevertheless, the authors have established"/>
 <result pre="the authors have established the antiviral activity of rilpivirine against" exact="ZIKV" post="in cell culture. Second, Sariyer et al.2 provided five"/>
 <result pre="provided five lines of evidence to support that rilpivirine targets" exact="ZIKV" post="RdRp (Figure 1A). (1) Computational docking suggests that rilpivirine"/>
 <result pre="design of analogs with improved potency. (2) The selection of" exact="ZIKV" post="variants resistant to rilpivirine will identify mutations that are"/>
 <result pre="al.2 demonstrated the in vivo efficacy of rilpivirine in a" exact="ZIKV" post="interferon α/β receptor (IFNAR)−/− mouse (type I interferon receptor"/>
 <result pre="cells, and neurons, but not neural progenitor cells. In addition," exact="ZIKV" post="infection caused significant inflammation and abundant apoptotic/necrotic cell damage."/>
 <result pre="good example of repurposing clinical drugs for potential treatment of" exact="ZIKV" post="infection. For any repurposed drug to work, the compound"/>
 <result pre="trials for the new indication.11 As rilpivirine inhibits HIV-1 and" exact="ZIKV" post="with EC50 in the single-digit nanomolar and micromolar range,"/>
 <result pre="single-digit nanomolar and micromolar range, respectively,2, 12 its potency against" exact="ZIKV" post="needs to be improved to ensure clinical efficacy in"/>
 <result pre="lead optimization could be tested against ZIKV. Because HIV-1 and" exact="ZIKV" post="may have different structure-and-activity (SAR) relationships, compounds with better"/>
 <result pre="have different structure-and-activity (SAR) relationships, compounds with better potency for" exact="ZIKV" post="may be identified from the rilpivirine analogs. Meanwhile, efforts"/>
 <result pre="A report from the Global Virus NetworkAntiviral Res.144201722324628595824 2SariyerI.K.GordonJ.BurdoT.H.WolleboH.GiantiE.DonadoniM.BellizziA.CicaleseS.LoomisR.RobinsonJ.A.Suppression of" exact="Zika" post="virus infection in the brain by the antiretroviral drug"/>
 <result pre="Infect. Dis.2201617017227623030 4BarrowsN.J.CamposR.K.PowellS.T.PrasanthK.R.Schott-LernerG.Soto-AcostaR.Galarza-MuñozG.McGrathE.L.Urrabaz-GarzaR.GaoJ.A Screen of FDA-Approved Drugs for Inhibitors of" exact="Zika" post="Virus InfectionCell Host Microbe20201625927027476412 5XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.Identification of small-molecule inhibitors of"/>
 <result pre="Zika Virus InfectionCell Host Microbe20201625927027476412 5XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.Identification of small-molecule inhibitors of" exact="Zika" post="virus infection and induced neural cell death via a"/>
 <result pre="Exp. Med.21420172843285728874392 8ChenQ.WuJ.YeQ.MaF.ZhuQ.WuY.ShanC.XieX.LiD.ZhanX.Treatment of Human Glioblastoma with a Live Attenuated" exact="Zika" post="Virus Vaccine CandidateMBio92018e01683-1830228241 9FerreiraA.C.Zaverucha-do-ValleC.ReisP.A.Barbosa-LimaG.VieiraY.R.MattosM.SilvaP.P.SacramentoC.de Castro Faria NetoH.C.CampanatiL.Sofosbuvir protects Zika"/>
 <result pre="Attenuated Zika Virus Vaccine CandidateMBio92018e01683-1830228241 9FerreiraA.C.Zaverucha-do-ValleC.ReisP.A.Barbosa-LimaG.VieiraY.R.MattosM.SilvaP.P.SacramentoC.de Castro Faria NetoH.C.CampanatiL.Sofosbuvir protects" exact="Zika" post="virus-infected mice from mortality, preventing short- and long-term sequelaeSci."/>
 <result pre="sequelaeSci. Rep.72017940928842610 10DengY.Q.ZhangN.N.LiC.F.TianM.HaoJ.N.XieX.P.ShiP.Y.QinC.F.Adenosine Analog NITD008 Is a Potent Inhibitor of" exact="Zika" post="VirusOpen Forum Infect. Dis.32016ofw17527747251 11ZouJ.ShiP.Y.Strategies for Zika drug discoveryCurr."/>
 <result pre="Potent Inhibitor of Zika VirusOpen Forum Infect. Dis.32016ofw17527747251 11ZouJ.ShiP.Y.Strategies for" exact="Zika" post="drug discoveryCurr. Opin. Virol.352019192630852345 12AzijnH.TirryI.VingerhoetsJ.de BéthuneM.P.KrausG.BovenK.JochmansD.Van CraenenbroeckE.PicchioG.RimskyL.T.TMC278, a next-generation"/>
 <result pre="and NNRTI-resistant HIV-1Antimicrob. Agents Chemother.54201071872719933797 13NobleC.G.LimS.P.AroraR.YokokawaF.NilarS.SehC.C.WrightS.K.BensonT.E.SmithP.W.ShiP.Y.A Conserved Pocket in the" exact="Dengue" post="Virus Polymerase Identified through Fragment-based ScreeningJ. Biol. Chem.29120168541854826872970 14RichnerJ.M.JaggerB.W.ShanC.FontesC.R.DowdK.A.CaoB.HimansuS.CaineE.A.NunesB.T.D.MedeirosD.B.A.Vaccine"/>
 <result pre="Identified through Fragment-based ScreeningJ. Biol. Chem.29120168541854826872970 14RichnerJ.M.JaggerB.W.ShanC.FontesC.R.DowdK.A.CaoB.HimansuS.CaineE.A.NunesB.T.D.MedeirosD.B.A.Vaccine mediated protection against" exact="Zika" post="virus induced congenital diseaseCell1702017273283.e1228708997 15DuanW.SongH.WangH.ChaiY.SuC.QiJ.ShiY.GaoG.F.The crystal structure of Zika"/>
 <result pre="against Zika virus induced congenital diseaseCell1702017273283.e1228708997 15DuanW.SongH.WangH.ChaiY.SuC.QiJ.ShiY.GaoG.F.The crystal structure of" exact="Zika" post="virus NS5 reveals conserved drug targetsEMBO J.36201791993328254839"/>
</results>
